MedTrace Logo

Ulinastatin in Severe Acute Pancreatitis

NCT01132521 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2018-01-17

No results posted yet for this study

Summary

This study aims to evaluate the effect of ulinastatin in the treatment and prevention of organ failure in severe acute pancreatitis.

Conditions

Interventions

DRUG

ulinastatin

Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

DRUG

placebo

Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • The first clinical college of harbin medical university

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Techpool Bio-Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yupei Zhao, MD · Peking Union Medical College Hospital

  • Chunyou Wang, MD · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01132521 on ClinicalTrials.gov